［1］KWONG YL,CHAN TSY,TAN D,et al.PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing Ⅰ-asparaginase［J］.Blood,2017,129(17):2437-2442．
［2］KRUG A,TARI G,SAIDANE A,et al.Novel T follicular helper-like T-cell lymphoma therapies:from preclinical evaluation to clinical reality［J］.Cancers（Basel),2022,14(10):2392.
［3］GOENKA R,BARNETT LG,SILVER JS,et al.Cutting edge:den-dritic cell-restricted antigen presentation initiates the follicular helper T cell program but cannot complete ultimate effector differentiation［J］.J Immunol,2011,187(3):1091-1095.
［4］DE LEVAL L,RICKMAN DS,THIELEN C,et al.The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma（AITL) and follicular helper T（TFH) cells［J］.Blood,2007,109(11):4952-4963.
［5］王红霞,张昶,陈昊,等.滤泡辅助性T细胞/B细胞/滤泡树突细胞免疫定位对血管免疫母细胞性T细胞淋巴瘤的辅助诊断意义［J］.中华病理学杂志,2019,48(1):40-42.
WANG HX,ZHANG C,CHEN H,et al.T follicular helper/B/follicular dendritic cell localization is useful in the diagnosis of angioimmunoblastic T cell lymphoma［J］. Chinese Journal of Pathology,2019,48(1):40-42.
［6］BREITFELD D,OHL L,KREMMER E,et al.Follicular B helper T cells express CXC chemokine receptor 5,localize to B cell follicles,and support immunoglobulin production［J］.J Exp Med,2000,192(11):1545-1552.
［7］LEAVENWORTH JW,VERBINNEN B,YIN J,et al.A p85alpha-osteopontin axis couples the receptor ICOS to sustained Bcl-6 expression by follicular helper and regulatory T cells［J］.Nat Immunol,2015,16(11):96-106.
［8］NURIEVA RI,CHUNG Y,MARTINEZ GJ,et al.Bcl6 mediates the development of T follicular helper cells［J］.Science,2009,325(5943):1001-1005.
［9］WITALIS M,CHANG J,ZHONG MC,et al.Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk［J］.Blood Adv,2020,4(5):868-879.
［10］GHIONE P,FARUQUE P,MEHTA-SHAH N,et al.T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma［J］.Blood Adv,2020,4(19):4640-4647.
［11］GALA R,GANDHI JS,GUPTA G,et al.Study of association of Epstein-Barr virus in lymphomas by Epstein-Barr virus-encoded RNA in situ hybridization:An Indian perspective from a tertiary care cancer institute［J］.Indian J Pathol Microbiol,2017,60(3):341-349.
［12］RHO R,LADDIS T,MCQUAIN C,et al.Miliary tuberculosis in a patient with Epstein-Barr virus-associated angioimmunoblastic lymphadenopathy［J］.Ann Hematol,1996,72(5):333-335.
［13］BALAKRISHNA JP,BHAVSAR T,NICOLAE A,et al.Human herpes virus 6（HHV-6)-associated lymphadenitis:Pitfalls in diagnosis in benign and malignant settings［J］.Am J Surg Pathol,2018,2(10):1402-1408.
［14］GILL H,IP AH,SO JC,et al.Disseminated cryptococcosis mimicking a lymphoma［J］.Eur J Haematol,2012,88(3):275-276.
［15］HELM TN,STECK WD,PROFFITT MR,et al.Kaposi's sarcoma,angioimmunoblastic lymphadenopathy,and antibody to HIV-1 p24 antigen in a patient nonreactive for HIV-1 with use of ELISA［J］.J Am Acad Dermatol,1990,23（2 Pt 1):317-318.
［16］ZHOU Y,ATTYGALLE AD,CHUANG SS,et al.Angioimmunoblastic T-cell lymphoma:Hstological progression associates with EBV and HHV6B viral load［J］.Br J Haematol,2007,138(1):44-53.
［17］WILLENBROCK K,BRAUNINGER A,HANSMANN ML.Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases［J］.Br J Haematol,2007,138(6):733-739.
［18］WANG C,MCKEITHAN TW,GONG Q,et al.IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma［J］.Blood,2015,126(15):1741-1752.
［19］ZENG H,HE H,GUO L,et al.Antibiotic treatment ameliorates Ten-eleven translocation 2（TET2) loss-of-function associated hematological malignancies［J］.Cancer Lett,2019,467:1-8.
［20］LI CS,PENG CN,JIANG ZP,et al.Ginkgo biloba extract inhibited cell proliferation and invasion by stimulating TET2 expression through miR-29a in colorectal carcinoma cells［J］.DNA and Cell Biology,2021,41(2):169-178.
［21］FIGUEROA ME,ABDEL-WAHAB O,LU C,et al.Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype,disrupt TET2 function,and impair hematopoietic differentiation［J］.Cancer Cell,2010,18(6):553-567.
［22］CHIBA S,SAKATA-YANAGIMOTO M.Advances in understanding of angioimmunoblastic T-cell lymphoma［J］.Leukemia,2020,34(10):2592-2606.
［23］SAKATA-YANAGIMOTO M,ENAMI T,YOSHIDA K,et al.Somatic RHOA mutation in angioimmunoblastic T cell lymphoma［J］.Nat Genet,2014,46(2):171-175.
［24］YAO WQ,WU F,ZHANG W,et al.Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell［J］.J Pathol,2020,250(3):346-357.
［25］ZANG S,LI J,YANG H,et al.Mutations in 5-methylcytosine oxidase TET2 and RhoA cooperatively disrupt T cell homeostasis［J］.J Clin Invest,2017,127(8):2998-3012.
［26］WILLEMSEN M,SCHOUTEN HC.Inappropriate costimulation and aberrant DNA methylation as therapeutic targets in angioimmunoblastic T-cell lymphoma［J］.Biomark Res,2017,5:6.
［27］ODEJIDE O,WEIGERT O,LANE AA,et al.A targeted mutational landscape of angioimmunoblastic T-cell lymphoma［J］.Blood,2014,123(9):1293-1306.
［28］YOO HY,KIM P,KIM WS,et al.Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma［J］.Haematologica,2016,101(6):757-763.
［29］DITORO D,WINSTEAD C,PHAM D,et al.Differential IL-2 expression defines developmental fates of follicular versus nonfollicular helper T cells［J］.Science,2018,361(6407):eaao2933.
［30］ITO Y,MAKITA S,TOBINAI K.Development of new agents for peripheral T-cell lymphoma［J］.Expert Opin Biol Ther,2019,19(3):197-209.
［31］MEHTA-SHAH N,MOSKOWITZ AJ,LUNNING M,et al.A phase Ⅰb/Ⅱa trial of the combination of romidepsin,lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas［J］.Blood,2016,128(22):2991.
［32］CHIAPPELLA A,DODERO A,EVANGELISTA A,et al.Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated peripheral T-cell lymphoma:Results of the PTCL13 phase Ⅰb/Ⅱ study［J］.Leukemia，2023，37(2):433-440.
［33］RAI S,KIM WS,ANDO K,et al.Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma:Phase Ⅱb results［J］.Haematologica,2023,108(3):811-821.
［34］ZHU J,YEOH EM,MAEDA Y,et al.Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy:A pooled analysis［J］.Leuk Lymphoma,2020,1(9):2145-2152.
［35］ADVANI RH,ANSELL SM,LECHOWICZ MJ,et al.A phase Ⅱ study of cyclophosphamide,etoposide,vincristine and prednisone（CEOP) alternating with pralatrexate（P) as front line therapy for patients with peripheral T-cell lymphoma（PTCL):final results from the T-cell consortium trial［J］.Br J Haematol,2016,172(4):535-544.
［36］LEMONNIER F,DUPUIS J,SUJOBERT P,et al.Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma［J］.Blood,2018,132(21):2305-2309.
［37］HORWITZ S,O'CONNOR OA,PRO B,et al.Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma（ECHELON-2):A global,double-blind,randomised,phase 3 trial［J］.Lancet,2019,393(10168):229-240.
［38］FUJISAWA M,SAKATA-YANAGIMOTO M,NISHIZAWA S,et al.Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma［J］.Leukemia,2018,32(3):694-702.
［39］NGUYEN TB,SAKATA-YANAGIMOTO M,FUJISAWA M,et al.Dasatinib is an effective treatment for angioimmunoblastic T-cell lymphoma［J］.Cancer Res,2020,80(9):1875-1884.
［40］KIM SJ,YOON DH,KANG HJ,et al.Bortezomib in combination with CHOP as first-line treatment for patients with stage Ⅲ/Ⅳ peripheral T-cell lymphomas:A multicentre，single-arm，phase 2 trial［J］.European Journal of Cancer,2012,48(17):3223-3231．
［41］马贝贝,冷加燕,马玉娟,等.来那度胺治疗血管免疫母细胞性 T 细胞淋巴瘤 3 例［J］.中国现代医学杂志,2020,30(9):122-123.
MA BB,LENG JY,MA YJ,et al.Lenalidomide in the treatment of 3 cases of angioimmunoblastic T-cell lymphoma［J］.China Journal of Modern Medicine,2020,30(9):122-123.
［42］HU P,BEN Y,LIU J,et al.Promising response to lenalidomide-combination therapy in a discordant lymphoma consisting of EBV-positive diffuse large B-cell lymphoma and angioimmunoblastic T-cell lymphoma:A case report［J］.Onco Targets Ther，2021，14:2489-2499.
［43］WANG Z,ZHOU H,XU J,et al.Safety and efficacy of dual PI3K-δ,γ inhibitor,duvelisib in patients with relapsed or refractory lymphoid neoplasms:A systematic review and Meta-analysis of prospective clinical trials［J］.Front Immunol，2023，13:1070660.
［44］CHEN Y,CHEN H,GU W,et al.Neoantigen-activated haploidentical T cell therapy for angioimmunoblastic T-cell lymphoma［J］.Clin Immunol,2020,210:108296.